| News
docdok.health increases safety of coronavirus vaccinations
23.02.2021
The Basel-based startup docdok.health has developed an app that aims to increase the safety and efficacy of COVID-19 vaccinations. The company has agreed a partnership with the German umbrella organization of specialized physicians (SpiFa).

As detailed in a press release, the Basel startup docdok.health AG is the new innovation and technology partner of SpiFa (Spitzenverband Fachärzte Deutschland), the German umbrella organization of specialized physicians. SpiFa has recommended to its members – some 160,000 doctors – that they should use an app developed by docdok.health after COVID-19 vaccinations.
The app can be used to collect data which is then anonymously forwarded on to the Paul Ehrlich Institute, otherwise known as the Federal Institute for Vaccines and Biomedicines in Germany. A broad database should also allow processes to be optimized, which will result in improved safety and efficacy for COVID-19 vaccinations.
“We see huge potential for our app in Switzerland”, comments Yves Nordmann, co-founder and Chief Medical Officer (CMO) of docdok.health, in the press release. Founded in 2017, docdok.health AG develops solutions to improve communications between doctor and patient. “The focus is on healthcare provision that prioritizes quality over quantity with the help of digital therapy solutions”, explains co-founder and CEO Ulrich Mühlner, who was also formerly a Senior Manager at Novartis.
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
Evolva launches new line for manufacturers of personal care products
Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...
Read MoreRecord figure for startups in the Basel Area
Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...
Read MoreNoema Pharma raises 103 million Swiss francs from investors
Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....
Read MoreWhy CDMO companies choose the Basel Area as their location
Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...
Read MoreBasel still the most attractive small city for business in Europe
As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...
Read MoreAriceum Therapeutics establishes subsidiary in Basel
The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...
Read More